Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$9.55
+1.4%
$8.70
$7.11
$11.90
$1.27B1.641.31 million shs4.37 million shs
OMDA
Omada Health
$17.61
-1.5%
$0.00
$14.14
$28.40
$460.15MN/A1.82 million shs1.16 million shs
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
$8.43
+4.7%
$7.19
$6.35
$15.21
$1.41B1.786.44 million shs18.17 million shs
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$14.33
-1.5%
$13.92
$9.90
$27.20
$1.19B0.411.16 million shs1.28 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
+1.38%+13.83%+5.18%-10.24%-2.75%
OMDA
Omada Health
-1.45%+15.86%+1,760,999,900.00%+1,760,999,900.00%+1,760,999,900.00%
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
+5.10%+22.04%+20.73%+3.84%-16.98%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-1.51%-2.65%+6.15%-0.76%+16.41%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
3.7982 of 5 stars
3.53.00.00.01.61.73.1
OMDA
Omada Health
N/AN/AN/AN/AN/AN/AN/AN/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
3.3613 of 5 stars
3.24.00.00.02.52.51.3
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
1.9101 of 5 stars
4.50.00.00.02.70.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
3.00
Buy$13.4040.31% Upside
OMDA
Omada Health
0.00
N/AN/AN/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
2.37
Hold$9.6013.89% Upside
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
2.90
Moderate Buy$37.56162.08% Upside

Current Analyst Ratings Breakdown

Latest OMDA, TDOC, VRDN, and AHCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.00
5/27/2025
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$10.00 ➝ $9.00
5/20/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/12/2025
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $13.00
5/8/2025
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$14.00 ➝ $13.00
5/8/2025
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$31.00 ➝ $27.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$46.00 ➝ $45.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $36.00
5/1/2025
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $12.00
(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$3.26B0.40$3.85 per share2.48$11.72 per share0.81
OMDA
Omada Health
N/AN/AN/AN/AN/AN/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
$2.57B0.58$5.85 per share1.44$8.66 per share0.97
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$300K3,897.28N/AN/A$6.09 per share2.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$90.42M$0.5716.759.851.092.63%6.96%2.40%8/5/2025 (Estimated)
OMDA
Omada Health
N/AN/A0.00N/AN/AN/AN/AN/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
-$1.00B-$5.92N/AN/AN/A-39.66%-11.01%-4.66%7/30/2025 (Estimated)
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$269.95M-$3.85N/AN/AN/A-102,092.39%-70.61%-44.67%8/14/2025 (Estimated)

Latest OMDA, TDOC, VRDN, and AHCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$0.95-$0.87+$0.08-$0.87$0.16 million$0.07 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
N/AN/AN/AN/AN/A
OMDA
Omada Health
N/AN/AN/AN/AN/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
N/AN/AN/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
1.25
1.29
1.07
OMDA
Omada Health
N/AN/AN/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
0.70
1.68
1.64
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.05
19.49
19.49

Institutional Ownership

CompanyInstitutional Ownership
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
82.67%
OMDA
Omada Health
N/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
76.82%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
1.55%
OMDA
Omada Health
N/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
0.58%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
1.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
10,500134.95 million132.86 millionOptionable
OMDA
Omada Health
84925.75 millionN/AN/A
Teladoc Health, Inc. stock logo
TDOC
Teladoc Health
5,500175.43 million174.42 millionOptionable
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
5081.59 million80.30 millionOptionable

Recent News About These Companies

Viridian Therapeutics: The Song Remains The Same
Viridian Therapeutics appoints Ajer to its board of directors

New MarketBeat Followers Over Time

Media Sentiment Over Time

AdaptHealth stock logo

AdaptHealth NASDAQ:AHCO

$9.55 +0.13 (+1.38%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$9.56 +0.01 (+0.16%)
As of 06/27/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.

Omada Health NASDAQ:OMDA

$17.61 -0.26 (-1.45%)
As of 06/27/2025 04:00 PM Eastern

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. We deliver virtual care between doctor’s visits, providing an engaging, personalized, and integrated experience for our members that is designed to improve their health while delivering value for the employers, health plans, health systems, pharmacy benefit managers (“PBMs”), and other entities that cover the cost of our programs. As of 2022, more than 156 million Americans suffered from one or more chronic conditions, such as obesity, prediabetes, diabetes, hypertension, and musculoskeletal (“MSK”) conditions, and approximately 40% of U.S. adults suffered from two or more chronic conditions, based on data published in the Annals of Bioethics & Clinical Applications. Managing these conditions—and treating the acute problems they can lead to—creates significant costs for employers, health plans, PBMs, and other entities that pay for the cost of care. According to the American Diabetes Association (the “ADA”)’s report “Economic Costs of Diabetes in the U.S. in 2022,” chronic diseases were the leading driver of U.S. medical spend, with diabetes alone accounting for $1 out of every $7 spent. According to research published in Diabetes Care, in 2022, an employee with type 2 diabetes cost on average an additional $7,000 annually due to increased medical costs, absenteeism, and lost productivity. The direct medical cost of people living with diabetes increased by 35% from 2012 to 2022, despite stable diabetes prevalence. It doesn’t have to be that way. Many chronic conditions can be managed or prevented at a more reasonable cost. One reason these conditions are often not managed efficiently is that the U.S. healthcare system was built mainly on encounter-based reimbursement models that pay for specific services, primarily as issues arise. Between what can be short and infrequent office visits, patients are often left to manage their condition on their own. Many have a hard time sticking to care plans and health goals—losing weight, eating better, exercising more—and have few resources to turn to for ongoing questions, accountability, and support as they work to change their lifestyle. Behavior change is hard. Omada was created to make it easier. Our virtual care programs are rooted in evidence and combine relationship-based, human-led clinical care with purpose-built technology. We call this approach Compassionate Intelligence. We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale. We sell our programs to customers that cover the cost for covered individuals. Our customers include employers that cover our programs for their employees and their dependents, health systems that cover our programs for patients, and any other entity that is financially responsible for costs of our programs for a population of covered lives. We also work closely with health plans and PBMs that either cover our programs for a portion of their members as our customers or act as channel partners reselling our programs to their own end customers. Our channel partners’ end customers typically consist of employers that cover our programs for their employees and their dependents. In general, our customers cover the cost of our programs for our members, except that members in our physical therapy program may incur copays, coinsurance, or deductibles, depending on plan design, much like in-person physical therapy. We launched our initial program in diabetes prevention and weight health in 2012, with the goal of showing that a virtual program could achieve the same clinical results as its in-person archetype. Through feedback from our customers, channel partners, members, and the market at large, we then recognized the need to create an integrated, multi-condition care platform to address multiple, commonly comorbid, chronic conditions. Today, we offer cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address MSK conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in our cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs. Since our founding, our programs have had a meaningful, positive impact. As of March 31, 2025, we had more than 2,000 customers and over 679,000 total members enrolled in one or more programs, and we had supported over one million members since launch. We count a member as enrolled in a program to the extent their participation was billed at least once in the preceding 12 months. We believe our programs serve a clear need for our customers and channel partners as well as our members, which is reinforced by our strong customer satisfaction and member engagement rates. In 2024, our average customer satisfaction rate for the year was over 90% for each of program implementation and customer success. Our customer satisfaction rate is based on survey results from customers that launched a new program during the measured period, and we consider a customer to be satisfied if they rated our program implementation and ongoing customer success, as applicable, at a 5 or higher on a 7-point scale. We believe that our customer satisfaction rates are strong and reflect the value of our services to customers. In 2024, more than 55% of members still engaged with our cardiometabolic programs at least once per month after a year in the program, and over 50% still engaged monthly after two years. We consider members to be still engaged after one year or two years in the program if, during their twelfth or twenty-fourth month of program participation in a cardiometabolic program, they complete at least one interaction with us, such as logging in or interacting with the Omada mobile app, sending messages to Omada Care Team members, or recording metrics such as weight, blood pressure, or blood glucose values. On average, in 2024, members in a cardiometabolic program engaged more than 30 times per month throughout their first year. Based on our experience and feedback from customers, we believe these engagement rates to be positive and to demonstrate the attractiveness of our program to members. We are proud of our progress, and we are just getting started. We have experienced strong growth since our inception. Revenue increased by 38% from $122.8 million to $169.8 million for the years ended December 31, 2023 and 2024, respectively, and by 57% from $35.1 million to $55.0 million for the three months ended March 31, 2024 and 2025, respectively. We continue to generate revenue from recurring customers, as evidenced by our net dollar retention rate, which for customers who were contracted as of the beginning of the prior period, is calculated as total billings generated in a particular period divided by total billings generated in the prior period and was 110% and 128% for the years ended December 31, 2023 and 2024, respectively. We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis. Our principal executive offices are located San Francisco, California.

Teladoc Health stock logo

Teladoc Health NYSE:TDOC

$8.43 +0.38 (+4.68%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$8.52 +0.09 (+1.04%)
As of 06/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.

Viridian Therapeutics stock logo

Viridian Therapeutics NASDAQ:VRDN

$14.33 -0.22 (-1.51%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$14.34 +0.01 (+0.03%)
As of 06/27/2025 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.